Paul E. Monahan

5.8k total citations
99 papers, 4.2k citations indexed

About

Paul E. Monahan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Paul E. Monahan has authored 99 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 49 papers in Genetics and 42 papers in Molecular Biology. Recurrent topics in Paul E. Monahan's work include Hemophilia Treatment and Research (54 papers), Virus-based gene therapy research (49 papers) and CAR-T cell therapy research (32 papers). Paul E. Monahan is often cited by papers focused on Hemophilia Treatment and Research (54 papers), Virus-based gene therapy research (49 papers) and CAR-T cell therapy research (32 papers). Paul E. Monahan collaborates with scholars based in United States, Germany and Netherlands. Paul E. Monahan's co-authors include R. Jude Samulski, Charles E. Toulson, Pooja Naik, Haiyan Fu, Douglas M. McCarty, Junjiang Sun, Chengwen Li, J. Michael Soucie, Christopher Walsh and Enni Lehtonen and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Paul E. Monahan

98 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul E. Monahan United States 36 2.3k 2.3k 1.3k 887 413 99 4.2k
Salima Hacein‐Bey‐Abina France 31 2.1k 0.9× 2.1k 0.9× 534 0.4× 1.1k 1.2× 233 0.6× 84 3.7k
H. Bobby Gaspar United Kingdom 32 1.7k 0.7× 1.4k 0.6× 783 0.6× 967 1.1× 208 0.5× 65 3.3k
Dennis D. Hickstein United States 33 1.1k 0.5× 2.0k 0.9× 1.1k 0.8× 423 0.5× 366 0.9× 118 3.9k
Els Verhoeyen France 35 1.7k 0.7× 2.2k 1.0× 304 0.2× 1.4k 1.6× 187 0.5× 114 4.1k
Martijn H. Brugman Netherlands 28 1.0k 0.4× 2.0k 0.9× 504 0.4× 720 0.8× 509 1.2× 51 3.1k
Christophe Hue France 16 1.5k 0.6× 1.7k 0.7× 298 0.2× 648 0.7× 179 0.4× 23 2.7k
Katherine P. Ponder United States 35 1.4k 0.6× 1.4k 0.6× 299 0.2× 320 0.4× 340 0.8× 83 3.4k
Suzanne M. K. Buckley United Kingdom 29 1.6k 0.7× 1.5k 0.6× 142 0.1× 526 0.6× 175 0.4× 65 2.5k
Fawzia Louache France 37 419 0.2× 1.0k 0.5× 1.6k 1.3× 827 0.9× 633 1.5× 92 3.8k
Erik C. Thorland United States 28 2.1k 0.9× 1.8k 0.8× 224 0.2× 542 0.6× 220 0.5× 61 4.2k

Countries citing papers authored by Paul E. Monahan

Since Specialization
Citations

This map shows the geographic impact of Paul E. Monahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Monahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Monahan more than expected).

Fields of papers citing papers by Paul E. Monahan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul E. Monahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Monahan. The network helps show where Paul E. Monahan may publish in the future.

Co-authorship network of co-authors of Paul E. Monahan

This figure shows the co-authorship network connecting the top 25 collaborators of Paul E. Monahan. A scholar is included among the top collaborators of Paul E. Monahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul E. Monahan. Paul E. Monahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pipe, Steven W., Wolfgang Miesbach, Michael Recht, et al.. (2025). Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine. 394(5). 463–474.
2.
Itzler, Robbin, Tyler W. Buckner, Frank W.G. Leebeek, et al.. (2024). Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia. 30(3). 709–719. 5 indexed citations
3.
4.
Konkle, Barbara A., Christopher Walsh, Miguel A. Escobar, et al.. (2020). BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 137(6). 763–774. 138 indexed citations
5.
Li, Min, et al.. (2020). Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy. Human Gene Therapy. 31(7-8). 448–458. 6 indexed citations
6.
Sun, Junjiang, Eric W. Livingston, Peter Johansen, et al.. (2019). Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding. Journal of Thrombosis and Haemostasis. 17(8). 1240–1246. 1 indexed citations
7.
Sun, Junjiang, Wenwei Shao, Xiaojing Chen, et al.. (2018). An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Molecular Therapy — Methods & Clinical Development. 10. 257–267. 27 indexed citations
8.
Weber, Alfred, et al.. (2018). Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua. Molecular Therapy — Methods & Clinical Development. 10. 29–37. 8 indexed citations
9.
Chapin, John & Paul E. Monahan. (2017). Gene Therapy for Hemophilia: Progress to Date. BioDrugs. 32(1). 9–25. 15 indexed citations
10.
Mazepa, Marshall, Paul E. Monahan, Judith Baker, Brenda Riske, & J. Michael Soucie. (2016). Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood. 127(24). 3073–3081. 89 indexed citations
11.
Antun, Ana G., Paul E. Monahan, Marilyn J. Manco‐Johnson, et al.. (2015). Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. Journal of Thrombosis and Haemostasis. 13(11). 1980–1988. 35 indexed citations
12.
13.
Monahan, Paul E., Andréa S. Doria, Rolf Ljung, & Víctor Jiménez‐Yuste. (2012). Optimizing joint function: new knowledge and novel tools and treatments. Haemophilia. 18(s5). 17–26. 6 indexed citations
14.
Monahan, Paul E., Judith Baker, Brenda Riske, & J. Michael Soucie. (2011). Physical Functioning in Boys with Hemophilia in the U.S.. American Journal of Preventive Medicine. 41(6). S360–S368. 34 indexed citations
15.
16.
Monahan, Paul E., Clinton D. Lothrop, Junjiang Sun, et al.. (2010). Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application. Molecular Therapy. 18(11). 1907–1916. 98 indexed citations
17.
Wardrop, Richard M., Ting Gui, Robert Maile, et al.. (2006). Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Therapy. 14(5). 429–440. 34 indexed citations
18.
Douvas, Michael G. & Paul E. Monahan. (2004). Life-Threatening Thrombosis Complicating the Management of Hepatic Hemorrhage: Anticoagulant Treatment in a Newborn With Hemophilia B. Journal of Pediatric Hematology/Oncology. 26(4). 258–263. 4 indexed citations
19.
Tenenbaum, Liliane, Enni Lehtonen, & Paul E. Monahan. (2003). Evaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors. Current Gene Therapy. 3(6). 545–565. 104 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Salima Hacein‐Bey‐Abina Breakdown of academic impact, for papers by H. Bobby Gaspar Breakdown of academic impact, for papers by Dennis D. Hickstein Breakdown of academic impact, for papers by Els Verhoeyen Breakdown of academic impact, for papers by Martijn H. Brugman Breakdown of academic impact, for papers by Christophe Hue Breakdown of academic impact, for papers by Katherine P. Ponder Breakdown of academic impact, for papers by Suzanne M. K. Buckley Breakdown of academic impact, for papers by Fawzia Louache Breakdown of academic impact, for papers by Erik C. Thorland
Rankless by CCL
2026